|
| Wednesday, 21 March 2018, 08:30 HKT/SGT | |
| |
|
|
|
|
| with Adjusted Net Profit of $25.3 Million; Achieving its 4th Consecutive Year of Solid Earnings |
HONG KONG, Mar 21, 2018 - (ACN Newswire) - Sisram Medical Ltd ("Sisram Med" or the "Company"; stock code: 1696.HK), a leading global provider of energy-based medical aesthetic treatment systems, today announced its audited consolidated annual results for the 12 months ended 31th December 2017 ("the year").
2017 was a pivotal year in the Company's history. Sisram Med became a publicly-traded company in September 2017 and is the first Israeli company to be listed on the Hong Kong Stock Exchange Main Board. The Company accelerated its transformation into a higher-margin business focused on value-creating, obtaining the best results in the history of the company while achieving a 16% revenue increase YOY with sales volume of $136.9 million in 2017 and adjusted net profit of $25.3 million.
Sisram Med experienced global growth of 21% in YOY revenues for its minimally-invasive platforms - 128% YOY growth in China, and over 150% YOY growth in India for this product line. During the year, the Company had significant collaboration with tier-one aesthetic firms in APAC, sustaining the leading position in the region and resulting in 27% YOY growth comprised of 121% YOY revenue growth in Hong-Kong and 38% revenue growth from the Indian subsidiary. In North America, the Company achieved revenue growth of 8% YOY and significantly expanded its North American salesforce and product offerings during the latter part of the year. EMEA revenues increased 13% YOY, primarily as a result of strong revenue growth in Poland, Spain, and the UK as well as from the DACH subsidiary, each of which maintained significant YOY revenue growth of at least 20%.
A significant portion of the Company's overall financial results can be attributed to its research and development efforts. R&D investment got big increase, as it continues to focus on new and innovative product offerings. Sisram Med is amongst the few companies to preform in-house organic research, development and manufacturing of multiple energy-based technologies including Laser, Radio Frequency, Light, Ultrasound and Plasma. This unique competitive edge enables the Company to quickly introduce wide variety of products, including both stand-alone and combined technologies to the market. In 2017, Sisram Med has allocated significant research, development and clinical efforts toward developing and testing new minimally-invasive treatments for surgical indications that the Company intends to launch in 2018.
In 2017, Sisram Med implemented a soft launch of Alma Smart Clinic, an Internet of Things ("IoT") platform, which is a cloud-based data center and remote-control service. In addition, the Company planned and executed a Direct to Customer ("DTC") strategy focused on strengthening its digital marketing tools and building a new distribution model. The goal of this strategy is to build bottom-up demand and strengthen brand awareness.
Mr. Yi Liu, Chairman and Executive Director of Sisram Medical Ltd, said, "Considering our accomplishments in 2017, our robust balance sheet, strong financial capability, solid funding channels and flexibility to fund our investments and operational commitments, I believe we are at an excellent position from which to continue our journey forward. Looking into the year of 2018, Sisram Med will continue to extend and deepen its value proposition, adhering its philosophy of 'Enhancing Quality of Life', delivering business results in the present, while creating value and opportunities for the future benefit of our shareholders, customers, suppliers and partners."
About Sisram Medical Ltd
Sisram Medical Ltd (1696.HK), the first Israeli company to be listed on the Hong Kong Stock Exchange Main Board, is an investment holding company specializing in medical technology for healthcare. Sisram Medical incorporated in 2013 in Israel, is a non-wholly owned subsidiary of Fosun Pharma, a leading healthcare group in China. The Company has also been the largest provider of energy-based medical aesthetic treatment systems in the PRC market and one of the leaders in the medical aesthetic treatment system market globally, in terms of revenue in 2016, according to the Medical Insight Report.
Sisram Medical - Enhancing Quality of Life.
Topic: Press release summary
Sectors: Daily Finance, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
Latest Press Releases
Shoucheng Holdings' First-Quarter Report Shows 18% Core Profit Growth and Sustained High Shareholder Returns
May 16, 2026 08:49 HKT/SGT
|
|
|
Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform
May 16, 2026 07:00 HKT/SGT
|
|
|
Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence
May 15, 2026 22:20 HKT/SGT
|
|
|
NEC completes construction of approximately 2,250 km EMCS submarine cable linking Pacific island nations
Friday, May 15, 2026 4:36:00 PM
|
|
|
Fujitsu and Science Tokyo launch joint research hub for quantum hardware advancement and talent development
Friday, May 15, 2026 4:12:00 PM
|
|
|
Fujitsu and IBM Japan formalize collaboration in healthcare sector
Friday, May 15, 2026 3:42:00 PM
|
|
|
Toyota Launches All-New Land Cruiser "FJ" Series in Japan
Friday, May 15, 2026 2:24:00 PM
|
|
|
Mitsubishi Motors Signs Memorandum of Understanding with FPT Japan Holdings to Study Collaboration in Software and Digital Domain
Friday, May 15, 2026 2:10:00 PM
|
|
|
Your Go-To Travel Checklist for Smarter, Reward-Focused Travel Planning
May 15, 2026 14:00 HKT/SGT
|
|
|
NEC Launches Orbital Transfer Vehicle Development Project Aiming for Asia's First Vehicle Deployment through JAXA's Space Strategy Fund Program
Friday, May 15, 2026 1:55:00 PM
|
|
|
|
|
More Press release >> |
|
|
|
